Zoetis (ZTS) Q1 2025 Earnings Call Transcript

Zoetis reported Q1 revenue of $2.2B (1% reported, 9% organic operational) and adjusted net income of $662M (4% reported, 6% organic). Management reaffirmed full-year revenue guidance of $9.425B–$9.575B (6%–8% organic), raised adjusted diluted EPS to $6.20–$6.30, and set adjusted net income guidance of $2.775B–$2.825B (5%–7% organic) while factoring a ~$20M enacted-tariff headwind. Growth was driven by companion-animal franchises—Simparica $367M (+19%), key dermatology $387M (+10%), OA pain mAbs $147M (+15%)—and management expects approval this year of a distinct long-acting OA mAb, supporting long-term franchise expansion.

Analysis

Zoetis’s quarter crystallizes an implicit structural shift: recurring-revenue franchises are becoming less clinic-locked and more subscription/retail-driven. That raises long-term customer lifetime value but creates a new battleground in channel economics—retail and home-delivery scale will improve compliance while also concentrating pricing and promotional pressure outside the clinic, compressing potential vet-captured margins and lifting the importance of direct-to-consumer ROI metrics.

Trade-policy noise is a near-term volatility amplifier rather than a fundamental breaker for Zoetis given its sizable US manufacturing footprint; however, the real second-order margin risk is longer and costlier: reshoring or dual-sourcing APIs to neutralize tariffs would raise fixed costs and capex and lengthen supply-chain lead times, turning a modest headline P&L hit into a multi-quarter operational investment cycle. FX is a double-edged sword — the current tailwind can flip quickly, so reported EPS gains tied to currency should be treated as transient until cash-flow trends confirm underlying organic momentum.

The incoming long-acting OA antibody is a strategic inflection with mixed effects: it should materially broaden use in low-frequency adherent owners and create a new high-price-per-admin option, but it also changes the cadence of per-patient revenue and can cannibalize existing monthly injectables if priced aggressively. That makes the drug’s regulatory timing and early real-world persistence data the principal catalysts to watch over the next 6–18 months; absent clear persistence gains, the benefit to enterprise economics is smaller and adoption remains education-dependent.

Key Decisions for Investors

• Long ZTS (Zoetis) shares or 12–18 month call options ahead of the long-acting OA mAb approval: asymmetric upside from a successful approval + favorable persistence data vs localized downside from tariff escalation or FX reversal. Trade size: 3–6% notional; target 12-month return +20–30%, stop -15% on tariff news or missed clinical/regulatory milestones.
• Pair trade — Long ZTS / Short ELAN (Elanco) 9–12 month horizon: Zoetis benefits from scale, diversified manufacturing and subscription economics; Elanco more exposed to price competition in livestock/parasiticides. Use a 0.6:0.4 notional hedge ratio to capture relative outperformance while limiting single-stock risk; unwind on clear share-of-market shifts or if tariffs materially reprice inputs.
• Tactical exposure to channel consolidation: buy a 6–12 month call spread on AMZN (e.g., buy-months 6–12 calls, sell higher strike) to capture upside from accelerated pet-med retail/subscription adoption. Small allocation (1–2% portfolio) given execution and regulatory uncertainty; take profits on a 30–50% option gain or cut if Amazon signals a major retail supplier conflict with vets.